Company news

NRX Pharmaceuticals, Inc. news in 2024

NRX Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

December 29, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024

November 25, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"

November 24, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Appoints Michael Abrams as Chief Financial Officer

November 17, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update

November 13, 2024

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024

November 12, 2024

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024

November 6, 2024

NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

October 30, 2024

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics

October 29, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

October 22, 2024

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic

October 2, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)

September 29, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update

August 13, 2024

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds

August 12, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing

June 27, 2024

NRx Pharmaceuticals (Nasdaq: NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024

May 6, 2024

NRx Pharmaceuticals (Nasdaq: NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression

May 5, 2024

NRx Pharmaceuticals (Nasdaq: NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression

April 29, 2024

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock

April 17, 2024

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections

April 16, 2024

NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock

April 16, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

April 14, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

April 7, 2024

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 31, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights

March 27, 2024

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

March 27, 2024

NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024

March 20, 2024

NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders

March 20, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders

March 17, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)

March 10, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

March 3, 2024

NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per Share

February 29, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)

February 11, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon

February 4, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

January 21, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination

January 16, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

January 15, 2024

Calls in 2024